Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds
Rhea-AI Summary
Vivos Therapeutics (Nasdaq: VVOS) closed the exercise of outstanding warrants and received approximately $4.64 million in gross proceeds on January 20, 2026. The exercised warrants covered an aggregate of 1,982,356 originally issued in 2023–2024 at reduced exercise prices of $2.34 per share. As consideration, the company issued private new unregistered warrants to purchase 3,964,712 shares at $2.09 per share with staggered expirations (24 months and five years). Shares issuable on the exercised warrants are registered on Form S-3; new warrants were offered via an exemption and resale registration will be filed. Proceeds are intended for working capital and general corporate purposes.
Positive
- Gross proceeds of approximately $4.64 million
- Shares issuable on exercised warrants registered on Form S-3
- Company will file resale registration for new private warrants
Negative
- Issued 3,964,712 new warrants at $2.09, creating dilution potential
- Existing warrants repriced to $2.34, reflecting discounted financing
- Placement agent fees and offering expenses will reduce net proceeds
News Market Reaction
On the day this news was published, VVOS declined 4.83%, reflecting a moderate negative market reaction. Argus tracked a trough of -5.3% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $900K from the company's valuation, bringing the market cap to $18M at that time. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VVOS showed a -3.27% pre-news move while only one peer (IINN) appeared on the momentum scanner, moving up 9.71%. Broader medical device peers showed mixed single‑stock moves, indicating stock-specific factors around VVOS’s warrant exercise and new warrant issuance.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 16 | Warrant exercise deal | Negative | -3.3% | Announced reduced-price warrant exercise and issuance of new private warrants. |
| Dec 16 | New center opening | Positive | +0.0% | Opened affiliated sleep testing and treatment center in Auburn Hills, Michigan. |
| Dec 15 | Investor fireside chat | Neutral | -2.4% | Announced online fireside chat to discuss strategy and growth plans. |
| Nov 19 | Q3 2025 results | Neutral | -4.5% | Reported strong revenue growth but larger losses and highlighted going-concern risk. |
| Nov 19 | Earnings scheduling | Neutral | -4.5% | Announced timing of Q3 2025 results release and conference call. |
Recent history shows VVOS often trading lower or flat around financings, earnings and corporate updates, with the prior warrant exercise news aligning with a negative price move.
Over recent months, VVOS has combined aggressive growth efforts with recurring capital raises. A November 10-Q highlighted strong revenue growth but ongoing losses and going-concern risk, followed by an expanded ATM capacity in October. Operationally, VVOS opened a new affiliated sleep center near Detroit and promoted its strategic pivot via an investor fireside chat. The January 2026 warrant exercise agreement, which generated gross proceeds of about $4.64M and added new warrants, set the stage for this closing announcement.
Regulatory & Risk Context
VVOS has an active Form S-3/A shelf dated 2025-09-05, with recent usage via 424B3 and 424B5 filings, indicating an established framework for recurring equity and warrant-related financings.
Market Pulse Summary
This announcement closes a previously agreed warrant inducement, delivering about $4.64M in gross proceeds while issuing 3,964,712 new unregistered warrants at $2.09. The structure fits VVOS’s broader pattern of using registered and private offerings under its Form S-3/A framework. Investors may track how this financing interacts with prior ATM capacity, the company’s going-concern disclosures, and progress in scaling its sleep-center–focused business model.
Key Terms
warrants financial
form s-3 regulatory
registration statement regulatory
private placement financial
AI-generated analysis. Not financial advice.
LITTLETON, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 1,982,356 shares originally issued in January 2023, November 2023 and February 20, 2024, at exercise prices ranging from
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
As consideration for the exercise of such existing warrants for cash, the Company issued in a private placement new unregistered warrants to purchase up to an aggregate of 3,964,712 shares of common stock at an exercise price of
Vivos intends to use the net proceeds from the offering for working capital and general corporate purposes.
The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the 1933 Act) and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements. The company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children.
OSA affects over 1 billion people worldwide, yet
Founded in 2016 and based in Littleton, Colorado, Vivos is working to change this. Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.
Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.
For more information, visit www.vivos.com
Cautionary Note Regarding Forward-Looking Statements
This press release, including statements of the Company’s management and other parties made in connection therewith, contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “would”, “should”, “expects”, “projects,” “potential,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal”. “aim” and variations of such words and similar expressions are intended to identify forward-looking statements. In this press release, forward-looking statements include, without limitation, those relating to the intended use of proceeds from the offering and the anticipated closing of the offering. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to continue to integrate business from the acquisition and alliance model into its own or otherwise implement sales, marketing and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector; (iv) the risk that Vivos may be unable to secure additional financing to continue operations, acquire additional sleep centers practices on reasonable terms, or maintain its Nasdaq listing when needed, if at all, (v) market and other conditions that could impact Vivos’ business or ability to obtain financing, and (vi) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Media Inquiries:
Jennifer Hauser, Executive Assistant to the CEO
Investor Relations Contact
investors@vivoslife.com
FAQ
How much did Vivos Therapeutics (VVOS) raise from the warrant exercises on January 20, 2026?
How many shares are covered by the new unregistered warrants issued by VVOS and at what exercise price?
What are the expiration terms for the new VVOS warrants issued in exchange for exercised warrants?
Will Vivos register the shares issuable upon exercise of the new private warrants (VVOS)?
What will Vivos use the net proceeds from the warrant exercises for (VVOS)?
Were placement agents used for the VVOS warrant exercise and who acted as agent?
